Phase IIIb Study of APD421 in Combination as PONV Prophylaxis
Launched by ACACIA PHARMA LTD · Jan 12, 2015
Trial Information
Current as of September 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female patients ≥ 18 years of age
- • Patients undergoing elective surgery (open or laparoscopic technique) under general anaesthesia, expected to last at least one hour from induction of anaesthesia to wound closure
- • Patients with at least 3 "Apfel" risk factors for PONV
- Exclusion Criteria:
- • Patients scheduled to undergo transplant surgery
- • Patients scheduled to receive only a local anaesthetic/regional neuraxial (intrathecal or epidural) block
- • Patients who are expected to remain ventilated for a period after surgery
- • Patients who are expected to need a naso- or orogastric tube in situ after surgery is completed
About Acacia Pharma Ltd
Acacia Pharma Ltd. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the management of chemotherapy-induced nausea and vomiting (CINV) and other related conditions. With a commitment to improving patient outcomes, Acacia Pharma leverages cutting-edge research to advance its product pipeline, which includes novel therapeutics designed to enhance the quality of life for patients undergoing cancer treatment. The company's expertise in pharmacology and clinical development, coupled with its patient-centric approach, positions Acacia Pharma as a leader in the oncology supportive care landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Kansas, United States
Columbus, Ohio, United States
Durham, North Carolina, United States
Boston, Massachusetts, United States
Miami, Florida, United States
Mulhouse, France
Cleveland, Ohio, United States
Stony Brook, New York, United States
Winston Salem, North Carolina, United States
Albany, New York, United States
San Francisco, California, United States
Boston, Massachusetts, United States
Aue, Germany
Houston, Texas, United States
Sheffield, Alabama, United States
Besançon, France
Bonn, Germany
Würzburg, Germany
Ludwigshafen, Germany
Strasbourg, France
Mainz, Germany
Bellaire, Texas, United States
Houston, Texas, United States
Lyon, France
Paris, France
Marburg, Germany
Patients applied
Trial Officials
Peter Kranke, MD
Principal Investigator
Würzburg University Hospitals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials